Abhishek S.’s Post

View profile for Abhishek S., graphic

General Manager BD&L driving global licensing and business growth.

Finally small molecules are doing big…. AZ is exploring the potential to use small molecule drugs to target RNA. Small molecule drugs have been the mainstay of the pharmaceutical industry for nearly a century. Defined as any organic compound with low molecular weight, small molecule drugs have some distinct advantages as therapeutics: most can be administered orally and they can pass through cell membranes to reach intracellular targets. They can also be designed to engage biological targets by various modes of action and their distribution can further be tailored, for example to allow for systemic exposure with or without brain penetration. Modulating biological disease driving pathways at the RNA level opens up new opportunities for previous undruggable targets

Small molecules

Small molecules

astrazeneca.com

Hareshh Ratwani

Independent Director I Advanced Corporate Strategy – IIMB I Pharmapreneur I Startup Founder & Director I Co-Founder I Startup Mentor | Corporate Governance Compliance I SBU Head – Emerging Markets |

8mo
Like
Reply
Bao Tran

Health Care enthusiast focusing on Pharmaceutical and Retail Pharmacies.

7mo

Great insight! Most small molecular drugs are invented to target protein which comprises the RNA. Since the new invention is targeting RNA instead, should this be classified as large molecule drug?

See more comments

To view or add a comment, sign in

Explore topics